Relationship of Prostate-Specific Antigen (PSA) and Prostate Volume in Patients with Biopsy Proven Benign Prostatic Hyperplasia (BPH)
Article Sidebar
Vol. 4 No. 2 (2020)
October 13, 2019
July 29, 2020
Abstract
Abstract
Â
Benign prostatic hyperplasia (BPH) is one of the most common benign tumors in men with prevalence ranging from 50% for men in their 60s to 90% for men in their 80s. The researcher sought to determine the relationship of prostate-specific antigen (PSA) and prostate volume in patients with benign prostatic hyperplasia. This study was based on 33 cases of benign prostatic hyperplasia in the Department of Urology, RSUD Dr. Soetomo Surabaya that diagnosed by histopathology examination. Cases with malignancy, acute urinary retention and prostatitis were excluded. The variables of prostate-specific antigen and prostate volume were examined. The results of this study found that 33 men were enrolled with mean PSA 16,04 ng/ml and a mean prostate volume of 49,13 ml. Overall, 84,8% had PSA level >4 ng/ml and 90,9% had prostate volume >25 ml. Prostate-specific antigen has significant correlation with prostate volume (p=0,019; r=0,362). This study concluded that prostate-specific antigen and prostate volume showed a significant correlation.
Â
Keywords            : benign prostatic hyperplasia, prostate specific antigen, prostate volume
Correspondence  : anny_sr@fk.unair.ac.id
References
Al-Khalil, S., Boothe, D., Durdin, T., Sunkara, S., Watkins, P., Yang, S., … de Riese, W. (2016). Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review. International Urology and Nephrology, 48(1), 91–97. https://doi.org/10.1007/s11255-015-1146-2
Deori, R., Das, B., & Rahman, M. A. (2017). A Study of Relationship of Prostate Volume, Prostate-Specific Antigen and age in Benign Prostatic Hyperplasia. International Journal of Contemporary Medical Research, 4(7), 1582–1586.
Dhingra, N., & Bhagwat, D. (2011). Benign prostatic hyperplasia: An overview of existing treatment. Indian Journal of Pharmacology. https://doi.org/10.4103/0253-7613.75657
Egan, K. B. (2016). The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urologic Clinics of North America, 43(3), 289–297. https://doi.org/10.1016/j.ucl.2016.04.001
Erdogan, A., Polat, S., Keskin, E., & Turan, A. (2019). Is prostate volume better than PSA density and free/total PSA ratio in predicting prostate cancer in patients with PSA 2.5–10 ng/mL and 10.1–30 ng/mL? Aging Male, 0(0), 1–7. https://doi.org/10.1080/13685538.2019.1578741
Haverkamp, K., Harder, L. K., Sophie, N., Kuhnt, M., Lüpke, M., Nolte, I., & Wefstaedt, P. (2019). Evaluation of canine prostate volume in calculated tomographic images - comparison of two assessment methods. 3, 1–12.
Jung, J. H., Ahn, S. V., Song, J. M., Chang, S., Kim, K. J., Kwon, S. W., & Park, S. (2016). Obesity as a Risk Factor for Prostatic Enlargement : A Retrospective Cohort Study in Korea. 321–328.
Kapoor, A. (2012). Benign prostatic hyperplasia (BPH) management in the primary care setting. Canadian Journal of Urology.
Kowalkouski, M. A., Goltz, H. H., Hart, S. L., & Latini, D. (2013). Prostate-Specific Antigen (PSA). In M. D. Gellman & J. R. Turner (Eds.), Encyclopedia of Behavioral Medicine (pp. 1547–1548). https://doi.org/10.1007/978-1-4419-1005-9_211
Krisna, D. M., Maulana, A., & Kresnoadi, E. (2017). Correlation between Prostate-Specific-Antigen (PSA) Level and Prostate Volume in Benign Prostatic Hyperplasia at Bhayangkara Hospital Mataram. Journal of Medicine and Health, 1(6), 525–531.
Lim, K. Bin. (2017). Epidemiology of clinical benign prostatic hyperplasia. Asian Journal of Urology, 4(3), 148–151. https://doi.org/10.1016/j.ajur.2017.06.004
Liu, J., Tang, J., Gong, D., & Kong, C. (2017). Level change of prostate-specific antigen in patients with benign prostatic hyperplasia after transurethral prostatic resection. Journal of Integrative Nephrology and Andrology, 4(1), 10. https://doi.org/10.4103/2394-2916.201276
Mao, Q., Zheng, X., Jia, X., Wang, Y., Qin, J., Yang, K., … Xie, L. (2009). Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia. International Urology and Nephrology, 41(4), 761–766. https://doi.org/10.1007/s11255-009-9533-1
Mochtar, C. A., Umbas, R., Soebadi, D. M., Rasyid, N., Noegroho, B. S., Poernomo, B. B., … Hamid, A. R. A. H. (2015). Pedoman Penatalaksanaan Klinis Pembesaran Prostat Jinak (Benign Prostatic Hyperplasia / BPH) (2nd ed.). Jakarta: Ikatan Ahli Urologi, Indonesia.
Patel, N. D., & Parsons, J. K. (2014). Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian Journal of Urology. https://doi.org/10.4103/0970-1591.126900
Putra, I. B. O. W., Hamid, A. R. A. H., Mochtar, C. A., & Umbas, R. (2016). Relationship of age, prostate-specific antigen, and prostate volume in Indonesian men with benign prostatic hyperplasia. Prostate International, 4(2), 43–48. https://doi.org/10.1016/j.prnil.2016.03.002
Rybalov, M., Breeuwsma, A. J., Leliveld, A. M., Pruim, J., Dierckx, R. A., & de Jong, I. J. (2013). Impact of total PSA, PSA doubling time, and PSA velocity on detection rates of11C-Choline positron emission tomography in recurrent prostate cancer. World Journal of Urology, 31(2), 319–323. https://doi.org/10.1007/s00345-012-0908-z
Sarma, A. V, Parsons, J. K., Mcvary, K., & Wei, J. T. (2009). Diabetes and Benign Prostatic Hyperplasia / Lower Urinary Tract Symptoms — What do We Know ? JURO, 182(6), S32–S37. https://doi.org/10.1016/j.juro.2009.07.088
Tang, J., & Yang, J. (2009). Etiopathogenesis of benign prostatic hyperplasia. Indian Journal of Urology. https://doi.org/10.4103/0970-1591.56179
Zhang, S., Qian, H., Zhao, Y., Sun, K., Wang, H., Liang, G., & Li, F. (2013). Relationship between age and prostate size. Asian Journal of Andrology, 15(1), 116–120. https://doi.org/10.1038/aja.2012.127
Authors
Qanun Medika by FK UM Surabaya is liscence under Lisensi Creative Commons Atribusi 4.0 Internasional.
